OUR PORTFOLIO COMPANIES

Our portfolio companies share a common goal – a fearless approach to addressing medical needs through bold ideas and transformative science. We discover, launch and build great companies based on bold ideas that meet at the intersection of science, strategy, business and medicine – where transformational science meets operational reality – providing the best opportunity to dramatically impact the lives of patients.

PUBLIC COMPANIES

AGIOS PHARMACEUTICALS

Agios Pharmaceuticals (NASDAQ: AGIO) is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism.

Focus: Cancer, Metabolic Disorders, Rare Genetic & Orphan Diseases, Personalized Medicine, Small Molecules
Phase of Development: Clinical
Year Invested: 2008
Location: Cambridge, Mass.

BLUEBIRD BIO

bluebird bio (NASDAQ: BLUE) has built an integrated product platform for severe genetic diseases and cancer through its lentiviral-based gene therapies, T cell immunotherapy expertise and genome editing capabilities.

Focus: Cancer, Rare Genetic & Orphan Diseases, Personalized Medicine, Gene Therapy
Phase of Development: Clinical
Year Invested: 2010
Location: Cambridge, Mass.

BLUEPRINT MEDICINES

Blueprint Medicines (NASDAQ: BPMC) is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases.

Focus: Cancer, Personalized Medicine, Small Molecules
Phase of Development: Clinical
Year Invested: 2011
Location: Cambridge, Mass.

CYTOMX

CytomX (NASDAQ: CTMX) is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform.

Focus: Cancer, Biologics
Phase of Development: Research & Preclinical
Year Invested: 2010
Location: South San Francisco, Calif.

EDITAS MEDICINE

Editas Medicine (NASDAQ: EDIT) is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes.

Focus: Rare Genetic & Orphan Diseases, Personalized Medicine, Gene Therapy
Phase of Development: Research & Preclinical
Year Invested: 2013
Location: Cambridge, Mass.

ELEVEN BIOThERAPEUTICS

Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) is a late clinical-stage company advancing a pipeline of novel anti-cancer agents based on the company's targeted protein therapeutics platform.

Focus: Cancer, Biologics, Small Molecules
Phase of Development: Clinical
Year Invested: 2010
Location: Cambridge, Mass.

FOUNDATION MEDICINE

Foundation Medicine (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer.

Focus: Cancer, Diagnostic, Personalized Medicine
Phase of Development: Commercial
Year Invested: 2010
Location: Cambridge, Mass.

GLOBAL BLOOD THERAPEUTICS

Global Blood Therapeutics (NASDAQ: GBT) is dedicated to discovering, developing and commercializing novel therapeutics to transform the treatment of patients with grievous blood-based disorders, including sickle cell disease.

Focus: Rare Genetic & Orphan Diseases, Personalized Medicine, Small Molecules
Phase of Development: Clinical
Year Invested: 2012
Location: South San Francisco, Calif.
### Public Companies

**Myokardia**
- **Focus:** Cardiovascular Disease, Rare Genetic & Orphan Diseases, Personalized Medicine, Small Molecules
- **Phase of Development:** Clinical
- **Year Invested:** 2012
- **Location:** South San Francisco, Calif.

**Voyager Therapeutics**
- **Focus:** Rare Genetic & Orphan Diseases, Neurologic/Psychiatric Diseases, Personalized Medicine, Gene Therapy
- **Phase of Development:** Clinical
- **Year Invested:** 2014
- **Location:** Cambridge, Mass.

**Alcresta Therapeutics**
- **Focus:** Neurologic/Psychiatric Diseases, Rare Genetic & Orphan Diseases, Small Molecules
- **Phase of Development:** Clinical
- **Year Invested:** 2011
- **Location:** Cambridge, Mass.

**Sage Therapeutics**
- **Focus:** Metabolic Disorders, Rare Genetic & Orphan Diseases, Small Molecules
- **Phase of Development:** Clinical
- **Year Invested:** 2011
- **Location:** Newton, Mass.

**Zafgen**
- **Focus:** Metabolic Disorders, Rare Genetic & Orphan Diseases
- **Phase of Development:** Clinical
- **Year Invested:** 2007
- **Location:** Cambridge, Mass.

### Private Companies

**Ablexis**
- **Focus:** Technology Platform, Biologics
- **Phase of Development:** Research & Preclinical
- **Year Invested:** 2009
- **Location:** San Francisco, Calif.

**Cibiem**
- **Focus:** Cardiovascular Disease, Device/Therapeutic Technology
- **Phase of Development:** Clinical
- **Year Invested:** 2008
- **Location:** Los Altos, Calif.

**Constellation Pharmaceuticals**
- **Focus:** Cancer, Personalized Medicine, Small Molecules
- **Phase of Development:** Clinical
- **Year Invested:** 2006
- **Location:** Cambridge, Mass.

**Corvia Medical**
- **Focus:** Cardiovascular, Device/Therapeutic Technology
- **Phase of Development:** Clinical
- **Year Invested:** 2009
- **Location:** Tewksbury, Mass.

**Zafgen** (NASDAQ: ZFGN)
- **Focus:** Metabolic Disorders
- **Phase of Development:** Clinical
- **Year Invested:** 2007
- **Location:** Cambridge, Mass.
<table>
<thead>
<tr>
<th><strong>PRIVATE COMPANIES</strong></th>
</tr>
</thead>
</table>

| **DECIBEL THERAPEUTICS** | Decibel Therapeutics is translating scientific advances in inner ear biology into novel therapies for people with hearing disorders.  
**Focus:** Otolaryngology  
**Phase of Development:** Research & Preclinical  
**Year Invested:** 2015  
**Location:** Cambridge, Mass. |
|--------------------------|

| **EDIMER PHARMACEUTICALS** | Edimer Pharmaceuticals was engaged in the research and development of treatments for rare dermatological diseases, including X-linked Hypohidrotic Ectodermal Dysplasia (XLHED). The company wound down operations in late 2016.  
**Focus:** Rare Genetic & Orphan Diseases, Personalized Medicine, Biologics  
**Year Invested:** 2009 |
|---------------------------|

| **ELEMENT SCIENCE** | Element Science is developing a novel therapeutic wearable that will allow patients at risk of sudden cardiac death to receive a potentially life-saving therapy.  
**Focus:** Cardiovascular Disease, Device/Therapeutic Technology  
**Phase of Development:** Research & Preclinical  
**Year Invested:** 2013  
**Location:** San Francisco, Calif. |
|-----------------------|

| **FULCRUM THERAPEUTICS** | Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease.  
**Focus:** Rare Genetic & Orphan Disease, Personalized Medicine, Small Molecules  
**Phase of Development:** Research & Preclinical  
**Year Invested:** 2016  
**Location:** Cambridge, Mass. |
|-------------------------|

| **GOLDFINCH BIO** | Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney disease.  
**Focus:** Renal, Personalized Medicine  
**Phase of Development:** Research & Preclinical  
**Year Invested:** 2016  
**Location:** Cambridge, Mass. |
|------------------|

| **IGENICA BIOThERAPEUTICS** | Igenica Biotherapeutics is focused on the discovery of innovative antibody-based therapies for the treatment of cancer.  
**Focus:** Cancer, Biologics  
**Phase of Development:** Clinical  
**Year Invested:** 2012  
**Location:** Burlington, Calif. |
|-----------------------------|

| **JOUNCE THERAPEUTICS** | Jounce Therapeutics is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients.  
**Focus:** Cancer, Biologics  
**Phase of Development:** Research & Preclinical  
**Year Invested:** 2013  
**Location:** Cambridge, Mass. |
|---------------------------|

| **KALA PHARMACEUTICALS** | Kala Pharmaceuticals is advancing novel nanoparticle-based treatments for ocular diseases, leveraging its proprietary mucus-penetrating particle (MPP) technology.  
**Focus:** Ophthalmology, Small Molecules  
**Phase of Development:** Clinical  
**Year Invested:** 2009  
**Location:** Waltham, Mass. |
|--------------------------|

| **MAGENTA THERAPEUTICS** | Magenta Therapeutics is harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases.  
**Focus:** Metabolic Disorders, Personalized Medicine  
**Phase of Development:** Research & Preclinical  
**Year Invested:** 2016  
**Location:** Cambridge, Mass. |
|--------------------------|

| **NEON THERAPEUTICS** | Neon Therapeutics is focused on developing novel therapeutics leveraging neoantigen biology to treat cancer.  
**Focus:** Cancer, Personalized Medicine, Technology Platforms, Small Molecules  
**Phase of Development:** Research & Preclinical  
**Year Invested:** 2015  
**Location:** Cambridge, Mass. |
|-------------------------|

| **NINEPOINT MEDICAL** | NinePoint Medical is a medical device company that designs, manufactures and sells an Optical Coherence Tomography (OCT) platform for clinical use for the evaluation of human tissue microstructure.  
**Focus:** Cancer, Diagnostic  
**Phase of Development:** Commercial  
**Year Invested:** 2009  
**Location:** Cambridge, Mass. |
|----------------------|

| **NURIX** | Nurix, Inc. is a leader in the discovery of small molecules that modulate the ubiquitin proteasome system (UPS) to address significant, unmet medical needs.  
**Focus:** Cancer, Small Molecules  
**Phase of Development:** Research & Preclinical  
**Year Invested:** 2013  
**Location:** San Francisco, Calif. |
|------------------|

| **PANOPTICA** | PanOptica is focused on licensing and developing a portfolio of exciting and innovative therapeutics for major ophthalmic diseases.  
**Focus:** Ophthalmology, Small Molecules  
**Phase of Development:** Clinical  
**Year Invested:** 2010  
**Location:** Bernardsville, NJ |
|----------------|

| **PLIANT THERAPEUTICS** | Pliant Therapeutics is harnessing the therapeutic capabilities of integrin biology and TGF-β signaling to develop breakthrough treatments for fibrotic diseases.  
**Focus:** Rare Genetic & Orphan Diseases, Respiratory, Small Molecules, Technology Platform  
**Phase of Development:** Research & Preclinical  
**Year Invested:** 2016  
**Location:** Redwood, Calif. |
|------------------------|

| **RELAY THERAPEUTICS** | Relay Therapeutics is committed making a transformative difference for patients by building the first dedicated drug discovery pipeline centered on protein motion.  
**Focus:** Protein Motion, Cancer, Small Molecules, Personalized Medicine  
**Phase of Development:** Research & Preclinical  
**Year Invested:** 2016  
**Location:** Cambridge, Mass. |
|----------------------|

| **REVOLUTION MEDICINES** | REVOLUTION Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines.  
**Focus:** Infectious Diseases, Biologics  
**Phase of Development:** Research & Preclinical  
**Year Invested:** 2015  
**Location:** Redwood, Calif. |
|-----------------------|
RHYTHM

Rhythm is developing peptide therapeutics for rare genetic metabolic diseases.

**Focus:** Gastrointestinal, Metabolic Disorders, Biologics

**Phase of Development:** Clinical

**Year Invested:** 2010

**Location:** Boston, Mass.

SEVENTH SENSE BIOSYSTEMS

Seventh Sense Biosystems is developing an array of products based on the company’s proprietary Touch Activated Phlebotomy (TAP™) painless blood collection platform.

**Focus:** Diagnostic

**Phase of Development:** Commercial

**Year Invested:** 2008

**Location:** Cambridge, Mass.

TOPICA PHARMACEUTICALS

Topica Pharmaceuticals, Inc. was focused on developing luliconazole for the treatment of onychomycosis, or fungal infections of the nail. The company wound down operations in 2016.

**Focus:** Infectious Diseases, Small Molecules

**Year Invested:** 2011

WARP DRIVE BIO

Warp Drive Bio is exploiting the molecules and mechanisms of nature to create transformative medicines.

**Focus:** Small Molecules

**Phase of Development:** Research & Preclinical

**Year Invested:** 2011

**Location:** Cambridge, Mass.

AFFERENT PHARMACEUTICALS (ACQUIRED BY MERCK IN 2016)

Afferent Pharmaceuticals developed first-in-class, proprietary, small molecule compounds that target P2X3 receptors for the treatment of chronic pain, respiratory and urology conditions.

**Focus:** Respiratory, Urology, Small Molecules

**Year Invested:** 2009

ALNARA PHARMACEUTICALS (ACQUIRED BY ELI LILLY AND COMPANY IN 2010)

Alnara designed innovative non-systemic protein therapeutics to make a difference for cystic fibrosis patients.

**Focus:** Metabolic Disorders, Rare Genetic & Orphan Diseases, Biologics

**Year Invested:** 2008

EMBER THERAPEUTICS (MERGED WITH MARIEL THERAPEUTICS IN 2016)

The combined company, known as Ember Therapeutics, Inc., is focused on developing regenerative medicines for disease modification of osteoarthritis, reversal of insulin resistance and the inhibition and reversal of organ fibrosis in diseases such as chronic kidney disease and Alport Syndrome.

**Focus:** Respiratory, Urology, Small Molecules

**Year Invested:** 2011

LOTUS TISSUE REPAIR (ACQUIRED BY SHIRE PLC IN 2013)

Lotus Tissue Repair developed first-in-class protein replacement therapy for the rare, genetic disorder DEB.

**Focus:** Rare Genetic & Orphan Diseases, Personalized Medicine, Biologics

**Year Invested:** 2011

MOTUS (ACQUIRED BY ALLERGAN IN 2016)

Motus is a biopharmaceutical company developing peptide therapeutics for the treatment of gastrointestinal (GI) diseases. Motus spun out of Rhythm Health in 2016.

**Focus:** Gastrointestinal, Metabolic Disorders

**Year Invested:** 2010

TARIS BIOMEDICAL (ACQUIRED BY ALLERGAN IN 2014)

TARIS Biomedical is developing a pipeline of innovative treatments for bladder diseases.

**Focus:** Urology, Device/Therapeutic Technology

**Year Invested:** 2011

THIRD ROCK PARTNERS

Alexis Borisy
Abbie Celniker, Ph.D.
Neil Exter
Kevin Gillis
Charles Homcy, M.D.

Mark Levin
Craig Muir
Cary Pfeffer, M.D.
Kevin Starr
Robert Tepper, M.D.

For more information about Third Rock, visit our website ThirdRockVentures.com or check us out on LinkedIn.

To learn more about career opportunities within the firm and our portfolio companies, please visit ThirdRockVentures.com/Careers-Overview or email us at trvtalent@thirdrockventures.com.